Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tiotropium + Olodaterol for Airway Remodeling in COPD
NCT05295355Unknown
- Sponsor
- Guangzhou Institute of Respiratory Health
- Start
- Jan 2021
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of olodaterol in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by Guangzhou Institute of Respiratory Health. Primary endpoint: Effect of Tiotropium Bromide Combined With Odaterol on endobronchial lumen area change at 52 weeks. Status: unknown.
02
Drugs
olodaterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT05295355.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05295355.